Cerivastatin, genetic variants, and the risk of rhabdomyolysis

The withdrawal of cerivastatin involved an uncommon but serious adverse reaction, rhabdomyolysis. The bimodal response, rhabdomyolysis in a small proportion of users, points to genetic factors as a potential cause. We conducted a case-control study to evaluate genetic markers for cerivastatin-associ...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Pharmacogenetics and genomics Ročník 21; číslo 5; s. 280
Hlavní autori:	Marciante, Kristin D, Durda, Jon P, Heckbert, Susan R, Lumley, Thomas, Rice, Ken, McKnight, Barbara, Totah, Rheem A, Tamraz, Bani, Kroetz, Deanna L, Fukushima, Hisayo, Kaspera, Rüdiger, Bis, Joshua C, Glazer, Nicole L, Li, Guo, Austin, Thomas R, Taylor, Kent D, Rotter, Jerome I, Jaquish, Cashell E, Kwok, Pui-Yan, Tracy, Russell P, Psaty, Bruce M
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.05.2011
Predmet:	Adult Aged Aged, 80 and over Aryl Hydrocarbon Hydroxylases - genetics Case-Control Studies Cytochrome P-450 CYP2C8 Female Genetic Variation Genome-Wide Association Study Glucuronosyltransferase - genetics Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use Liver-Specific Organic Anion Transporter 1 Male Middle Aged Organic Anion Transporters - genetics Polymorphism, Single Nucleotide Pyridines - adverse effects Pyridines - therapeutic use Rhabdomyolysis - chemically induced Rhabdomyolysis - genetics Risk Ryanodine Receptor Calcium Release Channel - genetics
ISSN:	1744-6880, 1744-6880
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!